INTRODUCTION
There are many infectious diseases which are not transmitted via the air-borne route. Such is the case with Rocky Mountain spotted fever. Studies in both man and animals have clearly established that transmission occurs through the bite of an infected tick and less frequently through abrasions in the skin contaminated with infected tick feces or tissue juices.
Recent studies indicate that aerosols of arthropod organisms, under certain conditions, can lead to disease (10, 20, 21, 24, 25) . To our knowledge, human infection due to aerosol exposure to Rickettsia rickettsii has not been documented. Rocky Mountain spotted fever of man has characteristic features which are remarkably similar to those of monkeys injected with infectious material (1, 27) . It remained for experimental studies to determine whether the portal of entry of the infectious agent alters the characteristics of the disease, its pathology, and the response to prophylactic and therapeutic measures. It is the purpose of this paper to describe the results observed in monkeys challenged with R. rickettsii by the respiratory route. TO PRIMARY CHALLENGE Clinical Aspects During the course of these studies (17) , rhesus and cynomolgus monkeys were exposed in a model 3 Henderson apparatus (7, 15) to aerosols of the RI strain (13) of R. rickettsii propagated in the yolk sac of developing chick embryos (23) . Assuming that the respiratory volume was about 1 liter (4) and that about 50% of the particles were retained (6) , the monkeys received challenges varying from 1.5 to 9,000 yolk sac LD50. Clinically obvious disease was observed in 56 of 60 (93.3 %) rhesus monkeys, and 42 of 56 (75.0%) died of specific infection 7 to 24 days postchallenge; 38 of 56 (67.9%) exhibited rash.
RESPONSE OF NORMAL MONKEYS
Clinical findings in the 56 rhesus monkeys that become ill after challenge are summarized in Table 1 The course of the illness in 14 surviving monkeys was highly variable. One monkey became acutely ill and was comatose for about 24 hr, but eventually recovered, whereas three monkeys showed only mild lethargy and anorexia. Intermediate gradations of disease were observed in the remaining 10 animals. Surviving monkeys usually were febrile for 5 to 7 days and ill for 7 to 10 days.
Heart sounds became less intense and muffled with, or shortly after, onset of acute illness, and this condition persisted until death of the animal or until recovery was definite. Only 12 of 56 (21.4%) monkeys showed respiratory symptoms. Dyspnea was observed, respectively, in five, two, and three animals during the early, acute, and late stages of the infection. Similarly, rales were detected in two, one, and one during these stages. The infrequency and irregularity with which respiratory signs were observed suggest that primary rickettsial pneumonia was not established after aerosol challenge, although serous pneumonitis was observed, microscopically, at autopsy (see below).
Rash, similar to that seen in man, was observed in 38 of 56 (67.9%) rhesus monkeys that became ill, and usually appeared 9 to 13 days On the other hand, the incubation period seemed to be inversely related to dose. For example, the means of the days on which monkeys became febrile after receiving less than 20, 20 to 200, 200 to 500, and more than 500 YsLD5o were 8.7, 6.4, 6.2, and 5.5 days, respectively. Similarly, the means of the days on which rash was first observed in animals in the four dose groups were 12.6, 11.2, 11.1, and 10.1 days, respectively.
Only eight cynomolgus monkeys were utilized in these studies. Two and six cynomolgus monkeys received 468 and 1,013 YSLD5o, respectively. All 8 died at 10 to 13 days postchallenge. The acute, rapidly fatal process noted in cynomolgus monkeys was similar to that observed in rhesus monkeys receiving similar doses. Laboratory Aspects Laboratory findings in rhesus monkeys exposed to aerosols of R. rickettsii included positive C-reactive protein (CRP) reactions, a rather dramatic left shift in neutrophils with or without leukocytosis, anemia, rickettsemia, and the appearance of OX-19 agglutinins and complement-fixing antibodies. CRP usually was first detected on the first day of fever, i.e., 1 to 3 days prior to appearance of other symptoms. All of 56 monkeys that became ill exhibited positive CRP reactions (Table 4) . CRP tests were positive until death in fatal infections and became negative 1 to 3 days after clinical improvement was noted in survivors. The left shift in the differential count was also apparent 1 to 3 days before onset of illness in all of 56 monkeys, except for 1 that became only mildly ill. Anemia was observed regularly in acutely ill animals 1 to 3 days after appearance of symptoms (Table 4) , but normal values were restored about 1 week after clinical improvement.
Rickettsemia was readily demonstrable 6 to 11 days postchallenge. A total of 47 blood samples taken from 10 monkeys at 1 to 18 days after exposure were inoculated into guinea pigs. As shown in Table 5 , none of 17 samples obtained 1 to 5 days after challenge yielded rickettsiae, whereas 14 of 20 (70.0%) samples drawn on the 6th through 11th days produced typical symptoms, febrile response, and complement-fixing Homogenates of tissues taken at autopsy from 13 monkeys with fatal infection were also inoculated into guinea pigs. R. rickettsii was isolated, respectively, from spleen, liver, kidney, lung, and brain of 9 of 13, 6 of 10, 6 of 7, 6 of 8, and 5 of 6 animals. Rickettsiae were recovered from heart blood in only one of five monkeys, although they were isolated from other tissues from all five.
All monkeys surviving long enough to allow serial serological studies showed significant rises in complement-fixing antibody titers ( In an attempt to establish the degree and duration of immunity conferred by vaccination, monkeys were challenged with aerosols of R. rickettsii at intervals up to 1 year after three weekly subcutaneous injections of 0.25 ml of commercial vaccine (Lederle Laboratories, Pearl River, N. Y.). In the first of four experiments (Table 7) , four vaccinated monkeys showed no clinical signs of illness after challenge with 650 YsLD50 at 3 weeks postvaccination, whereas two control monkeys exhibited typical symptoms and died on the 9th and 10th PED, respectively. Results of laboratory studies indicated that subclinical infection had been established in three of four vaccinated monkeys. For example, three of four exhibited positive tests for CRP and characteristic changes in the leukocytes; one of four showed a slight but significant fever, and all four showed significant increases in complement-fixing antibody titer after challenge.
Similarly, four monkeys challenged with 341 YSLD50 6 weeks after vaccination exhibited no symptoms after exposure, but laboratory evidence of infection was obtained in two of four, and all four showed significant rises in complementfixing antibody titer. Both control animals became acutely ill and died 11 and 12 days, respectively, after challenge.
In contrast, when monkeys were challenged 6 months postvaccination with 2,745 YSLD50, one of three became ill, and all three showed significant fever, positive CRP reactions, and characteristic changes in the differential count; however, all three survived. All three control animals Lecame acutely ill, and two of three exhibited typical rash. One or three died on the 9th PED, and the remaining two survived. When two monkeys In addition, four infected monkeys that had recovered after antibiotic therapy were rechallenged 1 year later with 1980 YSLD6o. None became ill, but all four exhibited significant fever and positive CRP tests, and three of four showed changes in the differential count. Three additional monkeys that had been vaccinated and challenged by aerosol 6 months later (see above) were challenged a second time in this experiment, i.e., 1 year after vaccination. The combination of vaccination and challenge resulted in solid immunity, in that all three monkeys remained well and all laboratory tests were negative. Three control animals died on the 10th or 11th day.
Thus, it would appear that as in man (29), infection apparently resulted in immunity of longer duration than did vaccination. None of 19 monkeys rechallenged 2, 6, or 12 months after recovery from established infection became ill. No illness was observed in monkeys challenged 6 weeks after vaccination. However, one of three and two of two challenged 6 and 12 months, respectively, after vaccination showed typical symptoms. One monkey exposed 12 months postvaccination exhibited extensive rash and died on the 10th day.
ANTIBiOTIc THERAPY AND PROPHYLAXIS
The response of monkeys infected by the aerosol route to appropriate antibiotic therapy was similar to that observed in man after natural infection. Therapy was not instituted in monkeys until at least 48 hr of significant fever and other signs consistent with well-established diesase were present. Monkeys treated with tetracycline, demethylchlortetracycline, and chloramphenicol became afebrile and asymptomatic within 1.5 AEROSOL INFECTION WITH R. RICKETTSI6 c Number dead per total number. to 3.5 days (16). Erythromycin estolate was somewhat less effective, and recovery occurred more slowly from 2 to 6 days after institution of therapy. As can be seen in Table 8 , only 4 of 50 treated monkeys died, whereas 12 of 14 untreated controls succumbed. Thus, the effectiveness of broad-spectrum antibiotics in treatment of naturally occurring Rocky Mountain spotted fever was also demonstrable when the respiratory route served as the portal of entry. Studies on prophylaxis (16) showed that administration of 30 and 50 mg/kg per day of demethylchlortetracycine and tetracycline, respectively, for 3 days prior to challenge merely delayed onset of symptoms for 2 days, and deaths occurred 4 to 5 days later than in control animals. When the same doses of each drug were given daily for 3 or 5 days, beginning with the day of exposure, signs of illness were delayed for about a week, but six of nine died as compared with one of two in controls.
STUDIES ON PERSISTENCE OF R. RiCKETTSII IN

MoNKEYS
Limited studies were conducted to determine whether R. rickettsii could be recovered from monkeys that survived infection spontaneously or after antibiotic therapy. In addition, previously vaccinated monkeys that were subsequently challenged were included.
Of 4 monkeys that recovered spontaneously and were sacrificed 25 to 75 days after challenge, R. rickettsii was isolated by guinea pig inoculation of splenic tissue from one monkey sacrificed on the 27th day. The spleens and other tissues of the other three failed to yield rickettsiae.
The only other monkey from which R. rickettsii was isolated had been treated successfully with demethylchlortetracycline for 7 days and sacrificed on the 48th day. The organism was isolated from a bronchial lymph node, but not from other tissues.
No isolates were obtained from 25 other treated monkeys sacrificed 25 to 75 days after challenge. Similarly, no isolates were obtained from 6 monkeys previously vaccinated and then sacrificed 27 to 98 days after challenge.
Although other avenues of approach may have yielded evidence of persistence of R. rickettsii in tissues of infected monkeys, these studies via guinea pig inoculation resulted in isolation in only two instances, 27 and 48 days after challenge. Various studies have demonstrated the presence or recrudescence of rickettsiae long after initial infection (9) . Attempts to activate infection with cortisone were not successful in 16 monkeys. It is conceivable that other stresses, such as X irradiation, or the use of tissue culture or immunofluorescence, may have resulted in detection of rickettsiae more frequently.
COMmuNiCABILrrY
During the entire course of these studies, there was no evidence either clinically or serologically of monkey-to-monkey transmission of disease. Normal monkeys kept in the same or adjacent cage showed no evidence of experience with R. rickettsii even when contacts were made shortly after aerosol challenge of test monkeys. This is consistent with observations of the nonappearance, in the absence of arthropod vectors, of naturally occurring infection in man (5) or of naturally occurring infection of guinea pigs, as seen in our laboratory. DISCUSSION There are occasions in the practice of medicine when the exact source or portal of entry of the infectious agent cannot be established with certainty. Similarly, in laboratory-acquired infections, there has been increasing evidence that infections have occurred in the absence of laboratory accidents or poor technique (26) . This has led to a greater appreciation of the potential role of "aerogenic transmission" of a wide variety of diseases. In recent years, studies of experimental tularemia in monkeys (3) and man (18, 19) have demonstrated the infectivity of aerosols of Francisella tularensis and have confirmed the suspicion that tularemia had been acquired in laboratories by the respiratory route (26) . These observations support other studies which have suggested that the respiratory tract could serve as a portal of entry even in arthropodborne infections, such as typhus, rickettsialpox, yellow fever (24), Venezuelan equine encephalomyelitis (10, 20, 21) , and St. Louis encephalitis (25) . Spencer As in man, high fever was a constant finding in monkeys exposed to aerosols of R. rickettsii, but morning remissions of fever seen in man (5, 29) were not observed in monkeys. The appearance of fever and symptoms 5 to 7 and 6 to 9 days, respectively, after aerosol exposure of monkeys is in agreement with the observed incubation period in man (29) . Also as in man, monkeys first showed lethargy and weakness, followed by acute illness terminating in prostration and coma. The abnormal heart sounds heard in monkeys during the acute stages were similar to those in man (2) .
Monkeys exposed to aerosols of R. rickettsii exhibited rash and peripheral necrosis similar to those observed in the naturally occurring infection in man, but the distribution of the rash was different. In monkeys, rash was observed most frequently on the extremities and head. Involvement of the trunk was limited to the lower back, perianal, and perineal regions. In the classic disease in man, rash begins on the wrists and ankles and spreads to the trunk, so that the entire body may be involved. None of the monkeys exposed to aerosols showed typical rash on the chest or abdomen. However, the rash in man may be minimal and fleeting in mild cases (5) . As in man, peripheral necrosis in monkeys usually involved only the ears and digits. In addition, necrosis of the tail, tip of the penis, and skin over the patella was noted in one monkey each.
Laboratory findings in monkeys exposed to R.
rickettsii aerosols were also similar to those in Rocky Mountain spotted fever in man. Anemia was observed regularly in acutely ill animals. A marked left shift of neutrophils was noted in 55 of 56 monkeys that became ill after exposure; about 50% exhibited significant leukocytosis. Although opinions differ as to the frequency with which changes in the leukocytes are observed in man, Harrell (5) has stated that, as the disease progresses, leukocytosis with a left shift in the differential leukocyte count is noted. Rickettsemia was readily demonstrable, by guinea pig inoculations, 6 to 11 days after exposure, but not during the first 5 days and only infrequently after the 11th day. In man, rickettsiae can be recovered from the blood throughout the 1st week of illness and during the first part of the 2nd week (5) with sufficient regularity to make the guinea pig infection test a reliable diagnostic procedure.
As in man, surviving monkeys showed OX-19 agglutinins and complement-fixing antibodies. All of 14 exhibited significant increases in complement-fixing antibodies, whereas significant titer changes were noted in only 10 Studies of the effectiveness of vaccination in monkeys and the response of monkeys to rechallenge provided further similarities in R. rickettsii infections in monkeys and man. None of 19 monkeys rechallenged 2, 6, or 12 months after recovery from established infection became ill. Vaccination was effective in preventing symptoms after challenge 6 weeks later, but one of three and two of two challenged 6 and 12 months, respectively, after vaccination showed typical symptoms, and one of two exposed 12 months postvaccination became acutely ill, exhibited typical rash, and died. It is generally agreed that, in man, recovery from infection confers a higher level of immunity of longer duration than does vaccination.
In addition, the response of infected monkeys to antibiotic therapy was similar to that observed in Rocky Mountain spotted fever in humans. Monkeys became afebrile and asymptomatic 1.5 to 3.5 days after institution of therapy with tetracycline, demethylchlortetracycline, or chloramphenicol. Erythromycin estolate was somewhat less effective, however. Chloramphenicol, chlortetracycline, oxytetracycline, and tetracycline have proved to be effective chemotherapeutic agents in human infections, but erythromycin failed to alter either the febrile or toxic course of the illness in two patients (29) .
Thus, throughout these studies of monkeys exposed to aerosols of R. rickettsii, remarkable similarities to the naturally occurring infection in man were observed. Additionally, the clinical picture in monkeys exposed to aerosols was similar to that observed by others in monkeys challenged by other than the respiratory route. From these results, it would be predicted that exposure of man to R. rickettsii aerosols would result in illness much like that observed after a tick bite. These studies in monkeys would suggest, therefore, that aerogenic transmission should be considered in infections of laboratory personnel who have had no known contact with ticks.
